Q&A. How does the conflict between UA & RU impact the pharma industry?

Webinar: How does the conflict between UA & RU impact the pharma industry?

Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And with good reason. Russia’s invasion of Ukraine affects millions of people, not just in this Eastern European nation but throughout the world. From delays throughout development, loss of business continuity, and risk of non-compliance for on-market products, there are many affected areas.

Trying to adapt to the situation?

Let’s talk how we can work together to adapt your strategy.

Who Should Attend?

Professionals from the following fields:

  • Clinical Research
  • Regulatory Affairs
  • Pharmacovigilance
  • Medical Information
  • Quality Assuranc

Duration: 55 min.

Speakers:

  • Regina Auškalnienė, Chief Global Clinical Research Officer
  • Martijn van de Leur, Head of Global Pharmacovigilance
  • Saulenė Kudarauskaitė, Quality Assurance Manager.
Regina Auškalnienė

Regina Auškalnienė

Chief Global Clinical Research Officer

Other content that might interest you:

Running A Clinical Trial In Georgia

Running A Clinical Trial In Georgia

Moving Clinical Trials away from Ukraine and Russia Russia, Ukraine, and other CIS countries have been significant contributors to clinical trials in many therapeutic areas for several years. With access to experienced investigators, good quality, and large patient...

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information